{"id":"vi-tt","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL3975020","moleculeType":"Small molecule","molecularWeight":"475.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains the Vi polysaccharide antigen from Salmonella typhi conjugated to tetanus toxoid (TT), which enhances immunogenicity by promoting T-cell dependent B-cell responses. This conjugate approach improves antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against typhoid fever.","oneSentence":"Vi-TT is a typhoid conjugate vaccine that stimulates immune responses against Salmonella typhi by presenting the polysaccharide capsule antigen conjugated to a protein carrier.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:15:12.526Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of typhoid fever caused by Salmonella typhi"}]},"trialDetails":[{"nctId":"NCT04852185","phase":"PHASE4","title":"Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana","status":"RECRUITING","sponsor":"International Vaccine Institute","startDate":"2021-08-24","conditions":"Typhoid Fever","enrollment":23000},{"nctId":"NCT05771779","phase":"PHASE3","title":"Co-administration Study of OCV, TCV and MR","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2023-10-14","conditions":"Typhoid, Cholera, Measles","enrollment":2117},{"nctId":"NCT05119426","phase":"PHASE4","title":"Effectiveness of a Typhoid Conjugate Vaccine in DRC","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2022-02-11","conditions":"Typhoid Fever","enrollment":48000},{"nctId":"NCT03554213","phase":"","title":"Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India","status":"COMPLETED","sponsor":"Stanford University","startDate":"2018-07-02","conditions":"Enteric Fever, Typhoid Fever, Salmonella Typhi Infection","enrollment":17292},{"nctId":"NCT04411290","phase":"","title":"Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases","status":"UNKNOWN","sponsor":"Umraniye Education and Research Hospital","startDate":"2020-05-15","conditions":"Thyroid Carcinoma, Thyroid Papillary Carcinoma, Multinodular Goiter, Adolescent","enrollment":200},{"nctId":"NCT00342628","phase":"PHASE2","title":"Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2006-07","conditions":"Typhoid Fever","enrollment":301}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Typbar TCV"],"phase":"marketed","status":"active","brandName":"Vi-TT","genericName":"Vi-TT","companyName":"International Vaccine Institute","companyId":"international-vaccine-institute","modality":"Biologic","firstApprovalDate":"","aiSummary":"Vi-TT is a typhoid conjugate vaccine that stimulates immune responses against Salmonella typhi by presenting the polysaccharide capsule antigen conjugated to a protein carrier. Used for Prevention of typhoid fever caused by Salmonella typhi.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}